{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T18:23:25Z","timestamp":1749407005789},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T00:00:00Z","timestamp":1708300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>This study aimed to assess weight gain associated with treatment switching to INSTI-based regimens in people living with HIV (PLWH) and to determine whether it is accompanied by worsening features of hypertension, dyslipidemia, or hyperglycemia.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this two-center retrospective observational study, we assessed weight gain and metabolic features in PLWH who switched to an INSTI-based regimen (study group) as compared to patients who remained on a non-INSTI regimen (control group) over a 24-month follow-up period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One-hundred seventy-four PLWH were included in the study group, and 175 were included in the control group. The study group gained 2.51\u2009kg\u2009\u00b1\u20090.31 (mean\u2009\u00b1\u2009standard deviation) over the 2 years of follow-up, while the control group gained 1.1\u2009\u00b1\u20090.31\u2009kg over the same time course (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). INSTI treatment, Caucasian origin, and lower BMI were risk factors associated with excessive weight gain during the 2 years of follow-up. Among metabolic parameters, only glucose levels increased after initiating INSTI-based regimens, although limited to males of African origin (<jats:italic>p<\/jats:italic>\u2009=\u20090.009).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>We observed a mild weight gain after switching to INSTI-based regimens, with no major impact on metabolic parameters over 2 years of follow-up. Longer follow-up might be needed to observe the adverse metabolic effects of INSTI-based regimens. The impact on weight gain should be discussed with every patient before the treatment switch to ensure a balanced diet and physical activity to prevent excessive weight gain that might hamper compliance with ART.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-024-09120-7","type":"journal-article","created":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:03:02Z","timestamp":1708354982000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The effect of a treatment switch to integrase Strand transfer inhibitor\u2013based regimens on weight gain and other metabolic syndrome-related conditions"],"prefix":"10.1186","volume":"24","author":[{"given":"Omer","family":"Maman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiessam Abu","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ofer","family":"Perzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Mahlab-Guri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Elbirt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hila","family":"Elinav","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,2,19]]},"reference":[{"key":"9120_CR1","unstructured":"Drug and food administration. Application number 22\u2013145 approval letter 2007. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2007\/022145_Isentress.cfm."},{"key":"9120_CR2","unstructured":"National institue of Health (.gov). Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents Living with HIV 2022 [cited 2022]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv\/what-start-initial-combination-regimens-antiretroviral-naive."},{"key":"9120_CR3","unstructured":"Arribas J MJ, Buckely RDM,Antinori A,Bracchi M,Calmy A,Dedes N,Horban A, Katlama C,Latysheva I,Lundgren JD, McCormack S,Mussini C,Pozniak A,Pulido F,Raffi F,Stelbrink HJ,Van der Vallk M, Vasylyev M. European AIDS clinical Society Guidlines 2021 [updated 10.2021; cited 2021 20.11.2021]. 11:[Available from: https:\/\/www.eacsociety.org\/guidelines\/eacs-guidelines\/."},{"issue":"16","key":"9120_CR4","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1001\/jama.2020.17025","volume":"324","author":"MS Saag","year":"2020","unstructured":"Saag MS, Gandhi RT, Hoy JF, Landovitz RJ, Thompson MA, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the international antiviral society-USA panel. JAMA. 2020;324(16):1651\u201369. Epub 2020\/10\/15. https:\/\/doi.org\/10.1001\/jama.2020.17025.","journal-title":"JAMA."},{"issue":"4","key":"9120_CR5","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","volume":"11","author":"A Kolakowska","year":"2019","unstructured":"Kolakowska A, Maresca AF, Collins IJ, Cailhol J. Update on Adverse Effects of HIV Integrase Inhibitors. Curr Treat Options Infect Dis. 2019;11(4):372\u201387. https:\/\/doi.org\/10.1007\/s40506-019-00203-7.","journal-title":"Curr Treat Options Infect Dis"},{"issue":"8","key":"9120_CR6","doi-asserted-by":"publisher","first-page":"2177","DOI":"10.1093\/jac\/dky145","volume":"73","author":"DRCL Bakal","year":"2018","unstructured":"Bakal DRCL, Luz PM, Clark JL, Boni RBD, Cardoso SW, Veloso VG, et al. Obesity following ART initiation is common and influenced by both traditional and HIV\u2212\/ART-specific risk factors. J Antimicrob Chemother. 2018;73(8):2177\u201385. https:\/\/doi.org\/10.1093\/jac\/dky145.","journal-title":"J Antimicrob Chemother"},{"key":"9120_CR7","volume-title":"Weight gain during treatment among 3,468 treatment-experienced adults with HIV","author":"GAEJ McComsey","year":"2019","unstructured":"McComsey GAEJ, Santiago S, Mounzer K, Moyle G, Vantig T, Sax PE, et al. Weight gain during treatment among 3,468 treatment-experienced adults with HIV. Seattle, Washington: Conference on retroviruses and opportunistic infections; 2019."},{"issue":"1","key":"9120_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1097\/QAD.0000000000002379","volume":"34","author":"JE Burns","year":"2020","unstructured":"Burns JE, Stirrup OT, Dunn D, Runcie-Unger I, Milinkovic A, Candfield S, et al. No overall change in the rate of weight gain after switching to an integrase-inhibitor in virologically suppressed adults with HIV. AIDS. 2020;34(1):109\u201314. https:\/\/doi.org\/10.1097\/QAD.0000000000002379.","journal-title":"AIDS."},{"issue":"7","key":"9120_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/cid\/ciz407","volume":"70","author":"K Bourgi","year":"2020","unstructured":"Bourgi K, Rebeiro PF, Turner M, Castilho JL, Hulgan T, Raffanti SP, et al. Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral Therapy. Clin Infect Dis. 2020;70(7):1267\u201374. https:\/\/doi.org\/10.1093\/cid\/ciz407. PubMed PMID: 31100116; PubMed Central PMCID: PMCPMC8205610","journal-title":"Clin Infect Dis"},{"issue":"9","key":"9120_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1056\/NEJMoa1904340","volume":"381","author":"C Kouanfack","year":"2019","unstructured":"Group NAS, Kouanfack C, Mpoudi-Etame M, Omgba Bassega P, Eymard-Duvernay S, Leroy S, et al. Dolutegravir-based or low-dose Efavirenz-based regimen for the treatment of HIV-1. N Engl J Med. 2019;381(9):816\u201326. https:\/\/doi.org\/10.1056\/NEJMoa1904340.","journal-title":"N Engl J Med"},{"key":"9120_CR11","volume-title":"Progressive rises in weight and clinical obesity for TAF\/FTC+DTG and TDF\/FTC+DTG versus TDF\/FTC\/EFV: ADVANCE and NAMSAL trials","author":"AVF Hill","year":"2019","unstructured":"Hill AVF, Delaporte E, Sokhela S, Kouanfack C, Moorhouse M, McCann K, et al. Progressive rises in weight and clinical obesity for TAF\/FTC+DTG and TDF\/FTC+DTG versus TDF\/FTC\/EFV: ADVANCE and NAMSAL trials. Mexico City: IAS 2019: conference on HIV pathogenesis; 2019."},{"issue":"3","key":"9120_CR12","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/cid\/ciz853","volume":"71","author":"AM Kerchberger","year":"2020","unstructured":"Kerchberger AM, Sheth AN, Angert CD, Mehta CC, Summers NA, Ofotokun I, et al. Weight Gain Associated With Integrase Stand Transfer Inhibitor Use in Women. Clin Infect Dis. 2020;71(3):593\u2013600. https:\/\/doi.org\/10.1093\/cid\/ciz853.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"9120_CR13","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1093\/cid\/ciz999","volume":"71","author":"PE Sax","year":"2020","unstructured":"Sax PE, Erlandson KM, Lake JE, McComsey GA, Orkin C, Esser S, et al. Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials. Clin Infect Dis. 2020;71(6):1379\u201389. https:\/\/doi.org\/10.1093\/cid\/ciz999.","journal-title":"Clin Infect Dis"},{"key":"9120_CR14","doi-asserted-by":"publisher","unstructured":"Saber SBA, Sparks A, Siegel M. Weight change associated with antiretroviral therapy switch to integrase Strand transfer inhibitor-based regimens. Open forum. Infect Dis Ther. 2019:6. https:\/\/doi.org\/10.1093\/ofid\/ofz360.407.","DOI":"10.1093\/ofid\/ofz360.407"},{"key":"9120_CR15","doi-asserted-by":"publisher","unstructured":"Erlandson KM, Carter CC, Melbourne K, Brown TT, Cohen C, Das M, et al. Weight change following antiretroviral therapy switch in people with viral suppression: pooled data from randomized clinical trials. Clin Infect Dis. 2021; https:\/\/doi.org\/10.1093\/cid\/ciab444. PubMed PMID: 33987636","DOI":"10.1093\/cid\/ciab444"},{"issue":"4","key":"9120_CR16","doi-asserted-by":"publisher","first-page":"ofx239","DOI":"10.1093\/ofid\/ofx239","volume":"4","author":"L Taramasso","year":"2017","unstructured":"Taramasso L, Ricci E, Menzaghi B, Orofino G, Passerini S, Madeddu G, et al. Weight Gain: A Possible Side Effect of All Antiretrovirals. Open Forum Infect Dis. 2017;4(4):ofx239. https:\/\/doi.org\/10.1093\/ofid\/ofx239.","journal-title":"Open Forum Infect Dis"},{"issue":"4","key":"9120_CR17","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/hiv.12294","volume":"17","author":"AC Achhra","year":"2016","unstructured":"Achhra AC, Mocroft A, Reiss P, Sabin C, Ryom L, de Wit S, et al. Short-term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:a:D study. HIV Med. 2016;17(4):255\u201368. Epub 2015\/07\/29. https:\/\/doi.org\/10.1111\/hiv.12294.","journal-title":"HIV Med"},{"issue":"1","key":"9120_CR18","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2337\/dc06-1075","volume":"30","author":"KWH Samaras","year":"2007","unstructured":"Samaras KWH, Law M, Emery S, Cooper D, Carr A. Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using international Diabetes Foundation and adult treatment panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care. 2007;30(1):113\u20139. https:\/\/doi.org\/10.2337\/dc06-1075.","journal-title":"Diabetes Care"},{"issue":"2","key":"9120_CR19","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1097\/QAI.0000000000001071","volume":"73","author":"M Herrin","year":"2016","unstructured":"Herrin M, Tate JP, Akgun KM, Butt AA, Crothers K, Freiberg MS, et al. Weight Gain and Incident Diabetes Among HIV-Infected Veterans Initiating Antiretroviral Therapy Compared With Uninfected Individuals. J Acquir Immune Defic Syndr. 2016;73(2):228\u201336. https:\/\/doi.org\/10.1097\/QAI.0000000000001071.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9120_CR20","doi-asserted-by":"publisher","first-page":"705","DOI":"10.3389\/fendo.2018.00705","volume":"9","author":"S Kumar","year":"2018","unstructured":"Kumar S, Samaras K. The Impact of Weight Gain During HIV Treatment on Risk of Pre-diabetes, Diabetes Mellitus, Cardiovascular Disease, and Mortality. Front Endocrinol (Lausanne). 2018;9:705. https:\/\/doi.org\/10.3389\/fendo.2018.00705.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"9120_CR21","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/j.ecl.2014.05.004","volume":"43","author":"PK Mankal","year":"2014","unstructured":"Mankal PK, Kotler DP. From wasting to obesity, changes in nutritional concerns in HIV\/AIDS. Endocrinol Metab Clin N Am. 2014;43(3):647\u201363. Epub 2014\/08\/30. https:\/\/doi.org\/10.1016\/j.ecl.2014.05.004.","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"12","key":"9120_CR22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1097\/QAD.0000000000003289","volume":"36","author":"J Milic","year":"2022","unstructured":"Milic J, Renzetti S, Ferrari D, Barbieri S, Menozzi M, Carli F, et al. Relationship between weight gain and insulin resistance in people living with HIV switching to integrase strand transfer inhibitors-based regimens. AIDS. 2022;36(12):1643\u201353. Epub 2022\/06\/22. https:\/\/doi.org\/10.1097\/QAD.0000000000003289.","journal-title":"AIDS."},{"issue":"9","key":"9120_CR23","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1056\/NEJMoa1902824","volume":"381","author":"WDF Venter","year":"2019","unstructured":"Venter WDF, Moorhouse M, Sokhela S, Fairlie L, Mashabane N, Masenya M, et al. Dolutegravir plus two different prodrugs of Tenofovir to treat HIV. N Engl J Med. 2019;381(9):803\u201315. Epub 2019\/07\/25. https:\/\/doi.org\/10.1056\/NEJMoa1902824.","journal-title":"N Engl J Med"},{"issue":"5","key":"9120_CR24","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/QAI.0000000000001525","volume":"76","author":"J Norwood","year":"2017","unstructured":"Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, et al. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens. J Acquir Immune Defic Syndr. 2017;76(5):527\u201331. https:\/\/doi.org\/10.1097\/QAI.0000000000001525.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"9","key":"9120_CR25","doi-asserted-by":"publisher","first-page":"e471","DOI":"10.1093\/cid\/ciaa177","volume":"71","author":"JE Lake","year":"2020","unstructured":"Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, et al. Risk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. Clin Infect Dis. 2020;71(9):e471\u2013e7. https:\/\/doi.org\/10.1093\/cid\/ciaa177.","journal-title":"Clin Infect Dis"},{"issue":"7","key":"9120_CR26","doi-asserted-by":"publisher","first-page":"e2234","DOI":"10.1093\/cid\/ciaa1403","volume":"73","author":"RRF JC","year":"2021","unstructured":"JC RRF, Bian A, Lake JE, Bourgi K, Moore RD, Horberg MA, et al. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada. Clin Infect Dis. 2021;73(7):e2234\u2013e42. https:\/\/doi.org\/10.1093\/cid\/ciaa1403.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"9120_CR27","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1097\/QAI.0000000000002447","volume":"85","author":"NA Summers","year":"2020","unstructured":"Summers NA, Lahiri CD, Angert CD, Aldredge A, Mehta CC, Ofotokun I, et al. Metabolic Changes Associated With the Use of Integrase Strand Transfer Inhibitors Among Virally Controlled Women. J Acquir Immune Defic Syndr. 2020;85(3):355\u201362. https:\/\/doi.org\/10.1097\/QAI.0000000000002447.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9120_CR28","doi-asserted-by":"publisher","first-page":"S176","DOI":"10.1093\/ofid\/ofz360.405","volume":"6","author":"MDJ Zimmerman","year":"2019","unstructured":"Zimmerman MDJ, Schafer JJ. Exploring the prevalence and characteristics of weight gain and other metabolic changes in patients with HIV infection switching to integrase inhibitor containing ART. Open Forum Infect Dis. 2019;6:S176\u20137. https:\/\/doi.org\/10.1093\/ofid\/ofz360.405.","journal-title":"Open Forum Infect Dis"},{"issue":"S2","key":"9120_CR29","doi-asserted-by":"publisher","first-page":"S181","DOI":"10.1093\/ofid\/ofz360.414","volume":"6","author":"RBL Hsu","year":"2019","unstructured":"Hsu RBL, Fusco JS, Mounzer K, Vannappagari V, Henegar C, van Wyk JA, et al. Risk of type 2 diabetes mellitus after antiretroviral therapy initiation in individuals living with HIV in the United States. Open Forun Infectious Diseases. 2019;6(S2):S181\u2013S2. https:\/\/doi.org\/10.1093\/ofid\/ofz360.414.","journal-title":"Open Forun Infectious Diseases"},{"key":"9120_CR30","doi-asserted-by":"publisher","first-page":"S38","DOI":"10.1093\/ofid\/ofz359.082","volume":"supp 2","author":"ALC Aldredge","year":"2019","unstructured":"Aldredge ALC, Summers NA, Mehta CC, Angert CD, Kerchberger AM, Sheri Weiser S, et al. Effects of Integrase Strand-Transfer Inhibitor Use on Lipids, Glycemic Control, and Insulin Resistance in the Women\u2019s Interagency HIV Study (WIHS). Open Forum Infect Dis. 2019;supp 2:S38. https:\/\/doi.org\/10.1093\/ofid\/ofz359.082.","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"9120_CR31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1056\/NEJM199701023360115","volume":"336","author":"K Mulligan","year":"1997","unstructured":"Mulligan K, Tai VW, Schambelan M. Energy expenditure in human immunodeficiency virus infection. N Engl J Med. 1997;336(1):70\u20131. Epub 1997\/01\/02. 8984340. https:\/\/doi.org\/10.1056\/NEJM199701023360115.","journal-title":"N Engl J Med"},{"key":"9120_CR32","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.antiviral.2016.05.013","volume":"132","author":"R Moure","year":"2016","unstructured":"Moure R, Domingo P, Gallego-Escuredo JM, Villarroya J, Gutierrez Mdel M, Mateo MG, et al. Impact of elvitegravir on human adipocytes: alterations in differentiation, gene expression and release of adipokines and cytokines. Antivir Res. 2016;132:59\u201365. Epub 2016\/05\/25. https:\/\/doi.org\/10.1016\/j.antiviral.2016.05.013.","journal-title":"Antivir Res"},{"issue":"10","key":"9120_CR33","doi-asserted-by":"publisher","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","volume":"71","author":"J Gorwood","year":"2020","unstructured":"Gorwood J, Bourgeois C, Pourcher V, Pourcher G, Charlotte F, Mantecon M, et al. The integrase inhibitors Dolutegravir and Raltegravir exert Proadipogenic and Profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes. Clin Infect Dis. 2020;71(10):e549\u2013e60. Epub 2020\/03\/14. https:\/\/doi.org\/10.1093\/cid\/ciaa259.","journal-title":"Clin Infect Dis"},{"issue":"8","key":"9120_CR34","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/cid\/ciy716","volume":"68","author":"V El Kamari","year":"2019","unstructured":"El Kamari V, Moser C, Hileman CO, Currier JS, Brown TT, Johnston L, et al. Lower Pretreatment Gut Integrity Is Independently Associated With Fat Gain on Antiretroviral Therapy. Clin Infect Dis. 2019;68(8):1394\u2013401. https:\/\/doi.org\/10.1093\/cid\/ciy716.","journal-title":"Clin Infect Dis"},{"key":"9120_CR35","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1038\/s41366-020-0551-5","volume":"44","author":"PVF Domingo","year":"2020","unstructured":"Domingo PVF, Giralt M, Domingo JC. Potential role of the melanocortin signaling system interference in the excess weight gain associated to some antiretroviral drugs in people living with HIV. Int J Obes. 2020;44:1970\u20133.","journal-title":"Int J Obes"},{"issue":"Suppl 5","key":"9120_CR36","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/hiv.12440","volume":"17","author":"F Raffi","year":"2016","unstructured":"Raffi F, Esser S, Nunnari G, Perez-Valero I, Waters L. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens. HIV Med. 2016;17(Suppl 5):3\u201316. Epub 2016\/10\/08. https:\/\/doi.org\/10.1111\/hiv.12440.","journal-title":"HIV Med"},{"issue":"3","key":"9120_CR37","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1080\/15284336.2018.1459343","volume":"19","author":"C Brites","year":"2018","unstructured":"Brites C, Nobrega I, Luz E, Travassos AG, Lorenzo C, Netto EM. Raltegravir versus lopinavir\/ritonavir for treatment of HIV-infected late-presenting pregnant women. HIV Clin Trials. 2018;19(3):94\u2013100. Epub 2018\/04\/10. https:\/\/doi.org\/10.1080\/15284336.2018.1459343.","journal-title":"HIV Clin Trials"},{"issue":"2","key":"9120_CR38","first-page":"103","volume":"11","author":"JA Munoz-Moreno","year":"2009","unstructured":"Munoz-Moreno JA, Fumaz CR, Ferrer MJ, Gonzalez-Garcia M, Molto J, Negredo E, et al. Neuropsychiatric symptoms associated with efavirenz: prevalence, correlates, and management. A neurobehavioral review AIDS Rev. 2009;11(2):103\u20139.","journal-title":"A neurobehavioral review AIDS Rev"},{"issue":"9692","key":"9120_CR39","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/S0140-6736(09)60918-1","volume":"374","author":"JL Lennox","year":"2009","unstructured":"Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796\u2013806. Epub 2009\/08\/04. https:\/\/doi.org\/10.1016\/S0140-6736(09)60918-1.","journal-title":"Lancet."}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09120-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09120-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,19]],"date-time":"2024-02-19T15:04:19Z","timestamp":1708355059000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09120-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9120"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09120-7","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,19]]},"assertion":[{"value":"8 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research was approved by the Hadassah-Hebrew University Medical Center Institutional Review Board (IRB) (0259\u201319-HMO) and the Kaplan Medical Center ethics committee (KMC-0036-10). Due to the retrospective design of the research, a waiver of informed consent of the participants in the study was provided by both ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable. Due to the retrospective design of the research, and the usage of anonymized data, a waiver of informed consent of the participants was approved by the both institutions ethics committees, thus approval for publication by the participants is not requested as well.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}